H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm’s previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Top 3 Trending Stocks, According to Analysts – 7/11/2025
- Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts
- Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating